| moxidectin / Generic mfg. |
| Completed | 3 | 224 | RoW | Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Zentel®, Placebo MOX, Placebo ALB | Jennifer Keiser, Public Health Laboratory Ivo de Carneri | Trichuriasis, Ascariasis, Hookworm Infections | 08/24 | 08/24 | | |
NCT03876262: Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis |
|
|
| Active, not recruiting | 3 | 323 | RoW | Moxidectin, Ivermectin | Medicines Development for Global Health | Onchocerciasis | 07/24 | 07/26 | | |
NCT04311671: Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole |
|
|
| Completed | 3 | 12997 | RoW | Moxidectin, Ivermectin, Albendazole | Medicines Development for Global Health | Onchocerciasis | 09/24 | 09/24 | | |
| Active, not recruiting | 3 | 164 | RoW | Ivermectin, Stromectol, Diethylcarbamazine, Diethylcarbamazine citrate, Hetrazan, Albendazole, Moxidectin | Washington University School of Medicine, Case Western Reserve University, Regional Hospital of Agboville, Southern Cote d'Ivoire | Lymphatic Filariasis | 09/24 | 09/24 | | |
StrongMoxy, NCT04056325: Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis |
|
|
| Enrolling by invitation | 2 | 210 | RoW | Moxidectin, Ivermectin, Placebo oral tablet | Jennifer Keiser, National Institute of Public Health, Vientiane, Laos, National Centre for Parasitology, Entomology and Malaria Control, Cambodia | Strongyloides Stercoralis Infection | 09/21 | 12/21 | | |
2019-001775-37: Dose-finding study of moxidectin for the treatment of scabies |
|
|
| Not yet recruiting | 2 | 36 | Europe | Moxidectin, Tablet, Moxidectin | Medicines Development Limited (trading as Medicines Development for Global Health), Medicines Development for Global Health Limited, Medicines Development Limited, Medicines Development for Global Health Limited | Scabies (infection with Sarcoptes scabiei), Scabies, Diseases [C] - Parasitic Diseases [C03] | | | | |
EOLoa, NCT04049851: Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients |
|
|
| Active, not recruiting | 2 | 72 | RoW | Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | Onchocerciasis, Ocular, Loiasis | 08/23 | 08/23 | | |
NCT05875441: Efficacy and Safety Study of Moxidectin in Adults With Scabies |
|
|
| Recruiting | 2 | 200 | US, RoW | Moxidectin Oral Product, Placebo | Medicines Development for Global Health | Scabies | 09/24 | 12/24 | | |
NCT06070116: Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis |
|
|
| Enrolling by invitation | 2 | 300 | RoW | Ivermectin w/ Albendazole, IA, Ivermectin + Diethylcarbamazine + Albendazole, IDA, Moxidectin + Albendazole, MoxA, Moxidectin + Diethylcarbamazine + Albendazole, MoxDA | Washington University School of Medicine, National Public Health Institute of Liberia | Onchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular, Onchocerca Infection, Tropical Disease | 09/26 | 09/26 | | |
